TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 140 filers reported holding TRAVERE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.82 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,945,624 | -36.2% | 1,671,770 | +9.6% | 0.09% | -34.1% |
| Q2 2023 | $23,420,928 | -29.0% | 1,524,800 | +4.0% | 0.14% | -33.2% |
| Q1 2023 | $32,964,762 | +77.3% | 1,465,752 | +65.8% | 0.20% | +60.3% |
| Q4 2022 | $18,596,030 | +3.7% | 884,262 | +21.4% | 0.13% | -11.3% |
| Q3 2022 | $17,941,000 | +32.7% | 728,114 | +30.5% | 0.14% | +35.2% |
| Q2 2022 | $13,518,000 | -43.3% | 557,903 | -39.7% | 0.10% | -34.4% |
| Q1 2022 | $23,849,000 | -18.2% | 925,444 | -1.5% | 0.16% | -17.9% |
| Q4 2021 | $29,149,000 | +16.4% | 939,092 | -9.0% | 0.20% | +15.4% |
| Q3 2021 | $25,036,000 | +116.9% | 1,032,398 | +30.5% | 0.17% | +116.7% |
| Q2 2021 | $11,540,000 | -27.9% | 790,931 | +23.4% | 0.08% | -36.6% |
| Q1 2021 | $16,010,000 | -9.1% | 641,172 | -0.8% | 0.12% | -20.1% |
| Q4 2020 | $17,608,000 | – | 646,050 | – | 0.15% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 895,821 | $8,008,640 | 3.99% |
| Deep Track Capital, LP | 7,370,000 | $65,887,800 | 2.54% |
| VR Adviser, LLC | 2,623,677 | $23,455,672 | 2.47% |
| Sio Capital Management, LLC | 884,770 | $7,909,844 | 2.45% |
| Kynam Capital Management, LP | 957,502 | $8,560,068 | 1.40% |
| MPM BioImpact LLC | 552,846 | $4,942,443 | 1.32% |
| ARMISTICE CAPITAL, LLC | 7,500,000 | $67,050,000 | 1.03% |
| Parkman Healthcare Partners LLC | 577,494 | $5,162,796 | 0.95% |
| Tri Locum Partners LP | 251,702 | $2,250,216 | 0.72% |
| Cheyne Capital Management (UK) LLP | 26,200 | $234,228 | 0.68% |